



Proven.
Prevention of delayed CINV (25-120 h) across 3 pivotal trials1-3
To request samples of VARUBI® or contact a VARUBI sales representative, call 877-VARUBI1 (877-827-8241).
CINV, chemotherapy-induced nausea and vomiting
References: 1. VARUBI® Prescribing Information, TerSera Therapeutics LLC 2. Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16(9):1079-1089. 3. Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16(9):1071-1078.